Literature DB >> 35146346

CURB-65 plus hypoalbuminemia: a new score system for prediction of the in-hospital mortality risk in patients with SARS-CoV-2 pneumonia.

Alessandra Oliva1, Cristian Borrazzo1, Maria Teresa Mascellino1, Ambrogio Curtolo1, Dania Al Ismail1, Francesca Cancelli1, Gioacchino Galardo2, Tommaso Bucci3, Giancarlo Ceccarelli1, Gabriella d'Ettorre1, Francesco Pugliese4, Claudio M Mastroianni1, Mario Venditti1.   

Abstract

INTRODUCTION: There is the need of a simple but highly reliable score system for stratifying the risk of mortality and Intensive Care Unit (ICU) transfer in patients with SARS-CoV-2 pneumonia at the Emergency Room.
PURPOSE: In this study, the ability of CURB-65, extended CURB-65, PSI and CALL scores and C-Reactive Protein (CRP) to predict intra-hospital mortality and ICU admission in patients with SARS-CoV-2 pneumonia were evaluated.
METHODS: During March-May 2020, a retrospective, single-center study including all consecutive adult patients with diagnosis of SARS-CoV-2 pneumonia was conducted. Clinical, laboratory and radiological data as well as CURB-65, expanded CURB-65, PSI and CALL scores were calculated based on data recorded at hospital admission.
RESULTS: Overall, 224 patients with documented SARS-CoV-2 pneumonia were included in the study. As for intrahospital mortality (24/224, 11%), PSI performed better than all the other tested scores, which showed lower AUC values (AUC=0.890 for PSI versus AUC=0.885, AUC=0.858 and AUC=0.743 for expanded CURB-65, CURB-65 and CALL scores, respectively). Of note, the addition of hypoalbuminemia to the CURB-65 score increased the prediction value of intra-hospital mortality (AUC=0.905). All the tested scores were less predictive for the need of ICU transfer (26/224, 12%), with the best AUC for extended CURB-65 score (AUC= 0.708).
CONCLUSION: The addition of albumin level to the easy-to-calculate CURB-65 score at hospital admission is able to improve the quality of prediction of intra-hospital mortality in patients with SARS-CoV-2 pneumonia.
Copyright © 2016 - 2021 InfezMed.

Entities:  

Keywords:  CALL score; CRP; CURB-65; ICU admission; PSI score; extended CURB-65; hypoalbuminemia; mortality

Year:  2021        PMID: 35146346      PMCID: PMC8805501          DOI: 10.53854/liim-2903-12

Source DB:  PubMed          Journal:  Infez Med        ISSN: 1124-9390


  33 in total

1.  Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study.

Authors:  W S Lim; M M van der Eerden; R Laing; W G Boersma; N Karalus; G I Town; S A Lewis; J T Macfarlane
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

2.  Is Albumin Predictor of Mortality in COVID-19?

Authors:  Francesco Violi; Roberto Cangemi; Giulio Francesco Romiti; Giancarlo Ceccarelli; Alessandra Oliva; Francesco Alessandri; Matteo Pirro; Pasquale Pignatelli; Miriam Lichtner; Anna Carraro; Francesco Cipollone; Damiano D'ardes; Francesco Pugliese; Claudio Maria Mastroianni
Journal:  Antioxid Redox Signal       Date:  2020-06-22       Impact factor: 8.401

3.  Comprehensive analysis of prognostic factors in hospitalized patients with pneumonia occurring outside hospital: Serum albumin is not less important than pneumonia severity assessment scale.

Authors:  Hiroyuki Miyazaki; Nobuhiko Nagata; Takanori Akagi; Satoshi Takeda; Taishi Harada; Shinichiro Ushijima; Takashi Aoyama; Yuji Yoshida; Hiroshi Yatsugi; Masaki Fujita; Kentaro Watanabe
Journal:  J Infect Chemother       Date:  2018-04-05       Impact factor: 2.211

4.  Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy.

Authors:  Graziano Onder; Giovanni Rezza; Silvio Brusaferro
Journal:  JAMA       Date:  2020-05-12       Impact factor: 56.272

5.  Prognostic Value of C-Reactive Protein in Patients With Coronavirus 2019.

Authors:  Xiaomin Luo; Wei Zhou; Xiaojie Yan; Tangxi Guo; Benchao Wang; Hongxia Xia; Lu Ye; Jun Xiong; Zongping Jiang; Yu Liu; Bicheng Zhang; Weize Yang
Journal:  Clin Infect Dis       Date:  2020-11-19       Impact factor: 9.079

6.  Albumin and C-reactive protein have prognostic significance in patients with community-acquired pneumonia.

Authors:  Jae Hyuk Lee; Jooyeong Kim; Kyuseok Kim; You Hwan Jo; JoongEui Rhee; Tae Youn Kim; Sang Hoon Na; Seung Sik Hwang
Journal:  J Crit Care       Date:  2010-12-03       Impact factor: 3.425

7.  Albumin caused the increasing production of angiotensin II due to the dysregulation of ACE/ACE2 expression in HK2 cells.

Authors:  Bi-Cheng Liu; Jun Gao; Qing Li; Li-Min Xu
Journal:  Clin Chim Acta       Date:  2008-12-24       Impact factor: 3.786

8.  Prediction for Progression Risk in Patients With COVID-19 Pneumonia: The CALL Score.

Authors:  Dong Ji; Dawei Zhang; Jing Xu; Zhu Chen; Tieniu Yang; Peng Zhao; Guofeng Chen; Gregory Cheng; Yudong Wang; Jingfeng Bi; Lin Tan; George Lau; Enqiang Qin
Journal:  Clin Infect Dis       Date:  2020-09-12       Impact factor: 9.079

9.  Hypoalbuminemia and clinical adverse events in children with COVID-19.

Authors:  Lorenzo Loffredo; Andrea Campana; Nicole Olivini; Nicola Cotugno; Paolo Palma; Alessandra Oliva; Guglielmo Salvatori; Anna Maria Zicari; Francesco Violi
Journal:  J Med Virol       Date:  2021-02-15       Impact factor: 2.327

10.  Clinical course and mortality risk of severe COVID-19.

Authors:  Paul Weiss; David R Murdoch
Journal:  Lancet       Date:  2020-03-17       Impact factor: 79.321

View more
  2 in total

1.  Comparison of Pneumonia Severity Indices, qCSI, 4C-Mortality Score and qSOFA in Predicting Mortality in Hospitalized Patients with COVID-19 Pneumonia.

Authors:  Isil Kibar Akilli; Muge Bilge; Arife Uslu Guz; Ramazan Korkusuz; Esra Canbolat Unlu; Kadriye Kart Yasar
Journal:  J Pers Med       Date:  2022-05-16

2.  Fibrosis-4 (FIB-4) Index and mortality in COVID-19 patients admitted to the emergency department.

Authors:  Tommaso Bucci; Gioacchino Galardo; Orietta Gandini; Tommasa Vicario; Carla Paganelli; Sara Cerretti; Chiara Bucci; Francesco Pugliese; Daniele Pastori
Journal:  Intern Emerg Med       Date:  2022-05-27       Impact factor: 5.472

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.